Kornimate/medical-research-clean huggingface dataset:
a study of the interruption on the mother-to-child transmission of hepatitis b virus （hbv mtct）in newborns at high risk

Conditions: Chronic Hepatitis B

Summary: chronic hepatitis b (chb) is a serious liver disease worldwide，hbv mtct is the important reason to keep high prevalence of chronic hbv infection in china. intrapartum infection is the main period of neonatal hbv infection. injecting hbig and hepatitis b vaccine immediately after birth is the most important method of blocking mother-to-child transmission of hbv. however, regular doses of hbig combined with hepatitis b vaccine blocking measures still have a failure rate as high as 5% \~ 15%.there are numerous studies to explore pregnancy women with hbv positive, especially high viral load of those women during pregnancy being treated with nucleoside analogs to increase the blocking rate of hbv mtct, but there is still a failure rate of 2.2% to 18%. in this study, we will explore the efficiency of personalized blocking method of hbv maternal-neonatal transmission in high-risk newborns,according to the venous blood hbsag state of neonatus at birth.

in this trial, the study population were consisted of patients suffering from chronic hepatitis b who had achieved hbeag positive and hbv dna \> 106 copies/ml and their newborns who were born with hbsag positive. before injecting hepatitis b vaccine and hbig for newborns, we tested their vein blood hbsag levels, and the venous blood hbsag positive newborns were randomly divided into the control group and the interventional group in which group we injected the additional 200 iu hbig within 24 hours after birth, in addition to routine injection. we gathered the neonatal venous blood of 0, 7 and 30 days to test the level of anti hbs, hbsag and hbv dna., then detected the level of anti hbs, hbsag and hbv dna when these children were seven months.according to the venous blood hbsag state of neonatus at birth, exploring the efficiency of personalized blocking method of hbv mtct in high-risk newborns.

Eligibility criteria:
inclusion criteria: * pregnant women who were chronic hepatitis b and had achieved hbeag positive and hbv dna \> 106 copies/ml * at birth the neonatal venous blood hbsag positive exclusion criteria: * active consumption of alcohol and/or drugs * co-infection with human immunodeficiency virus, hepatitis c virus, or hepatitis d virus, hiv, etc. * history of autoimmune hepatitis * psychiatric disease * evidence of neoplastic diseases of the liver * without gestational hypertension, premature rupture of membranes, antepartum haemorrhage diseases or amniotic fluid piercing history during pregnancy.

Keywords: chronic hepatitis b mother to child transmission interruption hepatitis b immunoglobulin pregnancy hbsag newborns
stem-pd open label extension (ole)

Conditions: Parkinson Disease; Parkinson's Disease and Parkinsonism

Summary: this study seeks to establish the safety and efficacy of extended twice daily treatments for treating symptoms associated with pd. only participants who completed the stem-pd rct trial are eligible for the ole.

up to 220 participants will enter an open label extension (ole) study during which all study participants will receive treatment for 12 weeks (84 days). study participants will be followed for 16 weeks (112 days) post treatment-cessation and then the twice daily treatments will be re-introduced for the final 8 weeks (56 days).

Eligibility criteria:
inclusion criteria: * completion of the study activities in the stem-pd rct trial. l. * participants must be willing and able to give consent to participate in the study trial. exclusion criteria: * participant anticipates being unable to attend all visits and complete all study activities in both the rct and ole study trial. * women of child-bearing potential who are pregnant or plan to become pregnant during the course of the rct or ole study trial.

Keywords: open label extension study medical devices non-motor symptoms (nms) non-invasive brain stimulation parkinson disease
artificial intelligence in the detection of right sided colonic polyp in different operator experience

Conditions: Colon Polyp

Summary: colonoscopy is the gold standard modality for the detection of colonic polyp. however, miss polyp occurs especially in right sided colon. artificial intelligence (ai) is one of the modality to improve polyp detection but the benefit of ai in operators with different endoscopic experience is still limited. this study aimed to evaluate the efficacy of ai in the detection of right sided colonic polyp in operators with different endoscopic experience by using double insertion of right side colon, back-to-back basis.


Eligibility criteria:
inclusion criteria: * participants age 40-80 years exclusion criteria: * history of colonic surgery (except appendectomy) * lower gastrointestinal bleeding * unstable vital sign during endoscopy of pregnancy * history of inflammatory bowel disease, polyposis syndrome, colon cancer, colonic stricture, abnormal coaglulation, organ failure

Keywords: colon polyp artificial intellegence colonoscopy
cognitive side effects of commonly prescribed medications in pediatric migraine

Conditions: Migraine

Summary: the purpose of this study is to determine if there are significant differences in the side effects related to memory, repetition and recall among these three drugs when used in a pediatric population.


Eligibility criteria:
inclusion criteria: * diagnosis of migraine with and without aura or chronic daily headache as defined by ihs * subjects must between the age of 8-17 (inclusive) exclusion criteria: * diagnosis of tension-type headache or cluster headache

Keywords: migraine
cognitive function analysis and qeeg study in long covid-19 syndrome patients

Conditions: Long COVID-19 Syndrome

Summary: over than 30% individuals with covid-19, including the asymptomatic ones, and around 80% of patients hospitalized with covid-19 may experience post-covid sequelae, which is commonly referred to as long covid syndrome. this condition has ties to decreased cognitive function and may lead to neuropsychiatric disorders but still need to be studied further. using a cross-sectional design, this study will analyze the relationship between cognitive function and neuropsychiatric disorders with brain wave activity in long covid patients. the investigators conducted assessments utilizing the quantitative electroencephalogram (qeeg) measurement method and interviews using instruments such as the moca questionnaire and self rating questionnaire (srq). with this qeeg examination, the investigators hoped that there will be an imbalance/abnormality of brain wave activity that arises related to impaired cognitive function.

this study is aimed to analyze the cognitive function and neuropsychiatry disorders with brain wave activity using qeeg that occurs after covid/long covid syndrome. the whole procedure will run for approximately 12 weeks based on the long covid range. the determinants of long covid patients include: never been vaccinated, old age, comorbid, female population, and hospitalized patients. the total number of subjects with the post-covid syndrome in the proportion test is 30 subjects. the measuring instruments used to measure the decline in cognitive function are the moca questionnaire and self rating questionnaire (srq). the target population is post-covid-19 patients with long covid syndrome. the accessible population is post-covid-19 patients who have been treated at rscm kiara and have regular checkups at the rscm polyclinic with long covid syndrome for 12 weeks or more. the control population is post-covid-19 patients who managed to recover without symptoms. the long covid syndrome patients who meet the inclusion criteria and have signed the consent.

Eligibility criteria:
inclusion criteria: 1. post-covid-19 patients with long covid-19 syndrome 2. over 18 years old 3. willing to participate in the research 4. completed the montreal cognitive assessment (moca) and self rating questionnaire (srq) exclusion criteria: 1. patients with neuropsychiatric disorders before being infected with covid-19

Keywords: long covid-19 syndrome covid-19 quantitative electroencephalography case-control study
place of birth and neonatal health in cases of premature birth between 32 and 36 weeks of amenorrhoea

Conditions: Premature Between 32 and 36 Weeks of Amenorrhoea

Summary: moderate and late premature babies (32-36 weeks of amenorrhoea) account for around 6% of births, but 20% of neonatal deaths. these children also have an increased risk of neonatal morbidity and long-term neurodevelopmental sequelae compared with full-term newborns. in the case of preterm birth, optimal antenatal, birth and postnatal management is necessary to prevent neonatal complications and mitigate longer-term consequences. however, we lack knowledge about the management of this at-risk population and the factors influencing their health. this knowledge is needed in the current context of unfavourable trends in neonatal health. over the last ten years, neonatal and infant mortality has stagnated in france, with france falling behind other european countries. according to the latest european report, france ranks 22nd out of 33 countries. the causes of this stagnation are not well known, but many hypotheses have been put forward, including sub-optimal organisation of care.


Eligibility criteria:
inclusion criteria: * all mothers and their newborn babies (live or stillborn) who had a delivery stay between 32 and 36 days of age recorded in the pmsi between 01/01/2015 and 31/12/2020. exclusion criteria: * births in very small maternity units * births in hospitals without an obstetrics unit * births outside hospitals.
segmental bronchoalveolar lavage

Conditions: Asthma; Pulmonary Fibrosis

Summary: bronchoalveolar lavage (bal) is a diagnostic and therapeutic procedure conducted by placing a small fiberoptic scope into the lung of a patient, and injecting sterile water (saline) into the lung and removing the fluid. the sterile solution removed contains secretions, cells, and protein from the lower respiratory tract. this sample can be analyzed to provide more information about possible disease processes going on in the lungs. this protocol will be used to perform bal, bronchial brushing, and bronchial wall biopsy in normal volunteers and patients with pulmonary disease. the samples collected during the study will be used to examine biochemical processes in the lung that may contribute to lung disease

this protocol proposes to perform bronchoalveolar lavage, bronchial brushing and bronchial wall biopsy in research volunteers and in patients with pulmonary disease to evaluate the cellular components of normal and diseased lungs. this research study will help to improve our understanding of pathogenic mechanisms in the lung during progression of pulmonary disease.

Eligibility criteria:
* inclusion criteria: patients and research volunteers will be accepted for bronchoscopy and bronchoalveolar lavage only if their heath status will not be compromised by the procedure. examples of disease that may be studied under this protocol include alpha-1 antitrypsin deficiency; lymphangioleiomyomatosis and the cystic lung disease; pulmonary fibrosis; and sarcoidosis. exclusion criteria: patients or research volunteers with abnormalities that contraindicate, or increase the risk of, fiberoptic bronchoscopy and bronchoalveolar lavage, including a history of allergy to atropine, lidocaine, or other topical anesthetics or premedications; fev(1) less than 0.8 liters; pao(2), on supplemental 02, of less than 70 mmhg or paco(2) greater than 45 mmhg; presence of uncorrected clotting disorder, uncontrolled hypertension, significant cardiac disease, renal or liver failure; metastatic disease; hematologic disorders such as severe anemia (hemoglobin less than or equal to 7 g/ml), granulocytopenia, or platelet disorders. patients or research volunteers with a positive serum test for human immunodeficiency virus or hepatitis b or c. the rationale for excluding participation on the basis of hiv seropositivity is because of the known effects of hiv on the lungs. patients or research volunteers who are pregnant or lactating. patients or research volunteers incapable of giving informed consent.

Keywords: cystic fibrosis healthy volunteers asthma normal volunteer chronic lung disease
one-year follow-up safety study in subjects previously implanted with vc-01™

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this trial is to evaluate the long-term safety in subjects previously implanted with vc-01™ combination product.


Eligibility criteria:
inclusion criteria: * previous implantation of vc-01™ combination product with subsequent explantation of all vc-01 units. exclusion criteria: * there are no exclusion criteria for this trial.
study to evaluate safety and immunogenicity of gsk biologicals' pandemic influenza (h1n1) candidate vaccine in children

Conditions: Influenza

Summary: the purpose of this study is to assess the safety and immunogenicity of two doses of the h1n1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.


Eligibility criteria:
inclusion criteria: all subjects must satisfy all the following criteria at study entry: * subjects who the investigator believes that their parent(s)/legally acceptable representative(s) (lars) can and will comply with the requirements of the protocol * children, male or female, aged between 8 and 12 weeks at the time of first study vaccination. * written informed consent obtained from the parent(s)/lar(s) of the subject. * healthy children, as established by medical history and clinical examination when entering the study. * parent/lar with access to a consistent means of telephone contact, land line or mobile, but not a pay phone or other multiple-user device. * born after a gestation period of \>= 36 to \<= 42 weeks. exclusion criteria: the following criteria should be checked at the time of study entry. if any exclusion criterion applies, the subject must not be included in the study: * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period. * acute disease at the time of enrolment. * any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing required). * history of any neurological disorders or seizures. * a family history of congenital or hereditary immunodeficiency. * receipt of systemic glucocorticoids within one month of study enrolment, or any other cytotoxic or immunosuppressive drug since birth. * administration of any vaccines within two weeks before study enrolment. * administration of immunoglobulins and/or any blood products since birth or planned administration during the study. * previous administration of any h1n1 vaccine, of any seasonal influenza vaccine. * previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus influenzae type b, and/or streptococcus pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations. * history of intercurrent diphtheria, tetanus, pertussis, poliomyelitis, haemophilus influenzae type b disease. * major congenital defects or serious chronic illness. * child in care. * any known or suspected allergy to any constituent of the influenza, dtpa-ipv/hib and pneumococcal study vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza, dtpa-ipv/hib and pneumococcal vaccine.

Keywords: gsk2340272a h1n1 pandemic influenza
metabolic syndrome and vitamin d level in old people

Conditions: Elderly; Metabolic Syndrome; Vitamin D Deficiency; Ostreocalcin; Insulin Resistance; Obesity; Osteoporosis; Sarcopenia

Summary: in 2012, a cross-sectional survey sampling 1,966 community-dwelling old people was conducted. structurized questionnaires were interviewed face-to-face by well-trained staffs. an overnight fasting blood were obtained for biochemistry parameters.


Eligibility criteria:
inclusion criteria: * more than 65-year-old exclusion criteria: * excluding empty houses, death, non-ambulatory subjects (subjects with significant disabilities, such as handicapped cerebral vascular accident, cancerous cachexia, unstable chronic diseases or psychiatric disorders, severe arthritis or inflammatory disease), uncomfortable anorexia by any medications, and non-reachable subjects
validation of human drugs target of repurposed drugs and novel therapies

Conditions: Rare Diseases; Aniridia; Neurotrophic Keratopathy; Limbal Stem Cell Deficiency; Ocular Graft-versus-host Disease; Ocular Cicatricial Pemphigoid; EEC Syndrome; Corneal Neovascularization

Summary: the cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance p expression is increased in reds associated with inflammation/pain. moreover, the following alternative targets are: vegf, pax6 and pro-inflammatory cytokine. the following procedures are performed specifically for the study: samples of blood, tear fluid and impression cytology. precisely during the ophthalmological exam performed according to normal clinical practice (uncorrected visual acuity, best spectacle corrected visual acuity, corneal topography, corneal pachymetry and the slit lamp pictures) investigator's team collect the samples of blood, tear fluid and impression cytology to evaluate the goal of the study.


Eligibility criteria:
inclusion criteria: inclusion criteria for study group * women and men with age equal or higher than 18 years (patients in reproductive age may be included in the study). * willingness and ability to read and understand the informed consent. * diagnosis (including genotype, if needed) of reds. inclusion criteria for control group * women and men with age equal or higher than 18 years (patients in reproductive age may be included in the study). * willingness and ability to read and understand the informed consent. * non - diagnosis of reds. exclusion criteria: exclusion criteria for study group patients who meet these criteria will be excluded from participation in the study: * pregnancy, breastfeeding. * active ocular infection. * descemetocele/impending corneal perforation. * recent (less than 3 months) ocular surgery. * recent (less than 1 month) change in topical medications type and frequency. exclusion criteria for control group patients who meet these criteria will be excluded from participation in the study: * pregnancy, breastfeeding. * active ocular infection. * descemetocele/impending corneal perforation. * recent (less than 3 months) ocular surgery. * recent (less than 1 month) change in topical medications type and frequency.

Keywords: rare eye diseases aniridia neurotrophic keratopathy limbal stem cell deficiency ocular graft-versus-host disease ocular cicatricial pemphigoid corneal neovascularization molecular targets cellular targets genomic targets nk1r pbmc substance p vegf blood tear impression cytology cytokine
the effect of fasudil on vascular function in humans

Conditions: Atherosclerosis; Hypercholesterolemia

Summary: the purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.


Eligibility criteria:
inclusion criteria: * coronary artery disease * hyperlipidemia -or- * healthy adults exclusion criteria: * unstable angina, myocardial infarction or revascularization within 3 months * symptomatic heart failure * creatinine \> 3.0 mg/dl * liver enzymes \> 3x upper limit of normal * chronic hypoxia * significant anemia * chronic inflammatory disease * pregnancy * willing to withdraw statins for duration of study
insole sensor to determine optimal limb loading in the rehabilitation of ankle fractures

Conditions: Ankle Fracture

Summary: the purpose of this study is to use a novel load monitoring technology to correlate limb loading to ankle fracture outcomes. this study will collect continuous limb loading data and will provide the first objective insight into how limb loading directs fracture healing.


Eligibility criteria:
inclusion criteria: * patient is 18 years of age or older * patient has an ankle fracture * patient speaks english * patient weighs between 100 and 250 pounds * patient lives in close enough proximity to the hospital to return for all appointments (\~100 miles) exclusion criteria: * patient is younger than 18 years of age * patient has multiple fractures that would alter weight bearing protocol * patient does not speak english * patient weighs less than 100 pounds or more than 250 pounds * patient does not live in close enough proximity to the hospital to return for all appointments (\~\>100 miles) * patient has a traumatic brain injury that would make it so they cannot consent * patient has diabetes
neonatal experience of social touch

Conditions: Premature Birth; Infant Development; Pain

Summary: the purpose of this randomised control trial is to determine the efficacy of ct-optimal touch (gentle stroking at 3cm/s) for newborn's who require a heel prick.

newborn infants are subject to several novel experiences that cause physiological, biochemical and behavioural indicators of stress; even routine and common events such as handling, changing a diaper or being bathed can increase salivary cortisol levels. excluding surgery and mechanical ventilation, the most common procedural pain sources in newborns are heel-lancing and venepuncture. tactile interventions such as skin to skin care and 'still containment hold' are widely used in clinical care with apparent positive results such as lower mean respiratory heart rate and pain measures, and higher oxygen saturation; yet, dynamic touch interventions have reported to be more beneficial than static touch interventions. a distinct type of nerve fibres, ct (c tactile) afferents, found exclusively in hairy skin, that respond optimally to gentle stroking at a velocity of \~1-10cm/s, are part of a system for processing pleasant and social rewarding touch. ct fibre activation also plays a role in pain inhibition and may be linked to the development of self-regulation, thereby, serving a neuroprotective function for the developing infant brain. here we will investigate whether tactile stimulation at ct-optimal velocity will reduce biochemical and physiological indicators of stress in infants, as determined by salivary cortisol, heart rate and blood oxygenation levels.

Eligibility criteria:
inclusion criteria: * the infant is born between 35 and 42 weeks. * require a heel prick * infants may be treated with antibiotics. * infants may be supported with non-invasive respiratory support. * infants may require blood sugar monitoring. * infants may be monitored for jaundice or infection. * written consent has been obtained from the person(s) with parental responsibility. exclusion criteria: * have a history of neurological problems. * receiving pharmacological analgesics. * known genetic condition. * breastfed babies * admitted to high dependency or intensive care * invasive respiratory support * receiving parenteral nutrition * has received any treatment for seizures * clinical instability in the judgment of nurses/midwives and paediatricians looking after the baby and mother.

Keywords: ct fibres affective touch